Adagene Inc (ADAG) stock price

Adagene Inc (ADAG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.28 (-2.67%), Market cap $0.23B, 52-week low–high $1.41 ~ $4.61.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and A

Key metrics

• Price: $3.28 (-2.67%)
• Market cap: $0.23B
• 52-week low–high: $1.41 ~ $4.61
• Sector: Healthcare
• Industry: Biotechnology
• Exchange: NASDAQ

Financial statements, price targets, institutional (13F) holdings and related news for Adagene Inc are updated in real time on BlackAll Trade.

Adagene Inc financial summary

Analyst outlook

• Analyst consensus: 3.3333

Key ratios · profitability · growth

• P/B ratio: 6.90
• Profit margin: -2.30%
• Operating margin: -0.75%

Frequently asked questions